Castañeda-Cruz MA, Francolugo-Vélez VA, Castañeda-Benítez JC

Language: Spanish
References: 23
Page: 15-21
PDF size: 529.39 Kb.

ABSTRACT

Introduction: To evaluate and document the population mean of prostate volume in cm³ obtained through suprapubic echosonography in healthy males between the ages of 19-25 years.
Materials and methods: Phase I: subject recognition, Phase II: random convenience sample of 100 healthy males under the age of 30 years made up of 63 participants after exclusion criteria, Phase III: sample sonogram study: measurements were obtained from the participants and communicated to them along with any other pertinent medical data found, Phase IV: statistical data analysis.
Results: Sample mean was 17.44 cm³, prostate volume populational mean interval was between 16.54-18.33 cm³. There were 3 types of ultrasonogram findings: 5 cases of posterior cyst, 6 calcifications due to amylaceous bodies and 1 ureterocele.
Conclusions: Prostate volume populational mean interval in males from 19-25 years old was between 16.54 and 18.33 cm³. The presence of a periurethral prostatic cyst was statistically significant because it resulted in healthy young males having a prostatic volume greater than the established parameter of 27 cm³ in adult males.

REFERENCES

1. Doo CK, Uh HS. Anatomic configuration of prostate obtained by noninvasive ultrasonography can predict clinical voiding parameters for determining BOO in men with LUTS. Urology 2009;73(2):232-6. Epub 2008 Nov 26.

2. Cabello Benavente R, Jara Rascón J, Monzó JI. Correlación ecográfico- anatómica de la medición del volumen prostático total y de la zona transicional mediante ecografía transrectal. Servicio de Urología, Hospital General Universitario Gregorio Marañón, Madrid. Actas Urol Esp 2006;30(2):175-80

3. Liu ZY, Xu CL, Gao X, Zhang LM. Volumes of total prostate and transitional zone are positively correlated with age in benign prostatic hyperplasia patients. Zhonghua Nan Ke Xue 2008;14(12):1103-5.

4. Orth M. Benign prostatic hypertrophy and the benign prostatic synd. Pharm Unserer Zeit 2008;37(4):315-21

5. Guan YJ, Pang ZL, Wei J, Cai ZT. Clinical significance of parameters of prostate volume measured by transabdominal ultrasonography in evaluating bladder outlet obstruction. Zhonghua Yi Xue Za Zhi 2008;88(14):977-9.

6. Kijvikai K. Digital rectal examination, serum prostatic specific antigen or transrectal ultrasonography: the best tool to guide the treatment of men with benign prostatic hyperplasia. Curr Opin Urol 2009;19(1):44-8.

7. Safarinejad MR. Prevalence of benign prostatic hyperplasia in a population- based study in Iranian men 40 years old or older. Int Urol Nephrol 2008;40(4):921-31. Epub 2008 Feb 2.

8. Bauer S. B, Anatomía y fisiología de la próstata, Walsh P. C, Retik A. B, Vaughan E. D, WEIN A. J, Urología de Campbell, 8ª edición, Editorial Médica Panamericana, Buenos Aires, 2008, pp 2090-2091.

9. Galosi AB, Montironi R, Fabiani A. Cystic lesions of the prostate gland: an ultrasound classification with pathological correlation. J Urol 2009;181(2):647-57. Epub 2008 Dec 16.

10. Akino H, Maekawa M, Nakai M. Ultrasound-estimated bladder weight predicts risk of surgery for benign prostatic hyperplasia in men using alpha-adrenoceptor blocker for LUTS. Urology 2008;72(4):817-20. Epub 2008 Jul 2.

11. Elwagdy S, Samy E, Sayed M, Gamal AH. Benign prostatic hyperplasia: clinical benefits on three-dimensional ultrasound extended imaging (3D-XI). Int J Urol 2008;15(4):332-9.

12. D’Ancona FC. Nonablative minimally invasive thermal therapies in the treatment of symptomatic benign prostatic hyperplasia. Curr Opin Urol 2008;18(1):21-7. Review.

13. Bosch JL, Bangma CH, Groeneveld FP. The long-term relationship between a real change in prostate volume and a significant change in lower urinary tract symptom severity in population-based men: the Krimpen study. Eur Urol 2008;53(4):819-25; discussion 825-7. Epub 2007 Aug 28.

14. Gattoni F, Avogadro A, Sacrini A. Transrectal prostatic echography in the study of hemospermia. An assessment of an 85-patient case load. Radiol Med 1996;91(4):424-8. Italian.

15. Kershaw LE, Hutchinson CE, Buckley DL. Benign prostatic hyperplasia: evaluation of T1, T2, and microvascular characteristics with T1- weighted dynamic contrast-enhanced MRI. J Magn Reson Imaging 2009;29(3):641-8.

16. Matthews PA. Getting ready for certification: medications for benign prostatic hyperplasia (BPH). Urol Nurs 2008;28(6):478-9.

17. Bethel CR, Chaudhary J, Anway MD, Brown TR. Gene expression changes are age-dependent and lobe-specific in the brown Norway rat model of prostatic hyperplasia. Prostate 2009;69(8):838-50.

18. Kaplan-Lefko PJ, Sutherland BW, Evangelou AI, Hadsell DL, Barrios RJ, Foster BA, Demayo F, Greenberg NM. Enforced epithelial expression of IGF-1 causes hyperplastic prostate growth while negative selection is requisite for spontaneous metastogenesis. Oncogene 2008;27(20):2868-76. Epub 2007 Nov 19.

19. Yan J, Brown TR. Cell proliferation and expression of cell cycle regulatory proteins that control the G1/S transition are age dependent and lobe specific in the brown norway rat model of prostatic hyperplasia. Endocrinology 2008;149(1):193-207. Epub 2007 Oct 25

20. Berger AP, Bartsch G, Deibl M. Atherosclerosis as a risk factor for benign prostatic hyperplasia. BJU Int 2006;98(5):1038-42. Epub 2006 Jul 28.

21. Toh KL, Ng CK. Urodynamic studies in the evaluation of young men presenting with lower urinary tract symptoms. Int J Urol 2006;13(5):520-3.

22. Shariat SF, Ashfaq R, Roehrborn CG. Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia. J Urol 2005;174(5):2046-50.

23. Kok ET, Schouten BW, Bohnen AM. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study. J Urol 2009;181(2):710-6. Epub 2008 Dec 16.